CZ291039B6 - Monoklonální protilátka, hybridom, polypeptid a způsob jeho přípravy, izolovaná DNA, rekombinantní vektor, hostitelská buňka, humanizovaná protilátka a farmaceutický prostředek - Google Patents

Monoklonální protilátka, hybridom, polypeptid a způsob jeho přípravy, izolovaná DNA, rekombinantní vektor, hostitelská buňka, humanizovaná protilátka a farmaceutický prostředek Download PDF

Info

Publication number
CZ291039B6
CZ291039B6 CZ19941910A CZ191094A CZ291039B6 CZ 291039 B6 CZ291039 B6 CZ 291039B6 CZ 19941910 A CZ19941910 A CZ 19941910A CZ 191094 A CZ191094 A CZ 191094A CZ 291039 B6 CZ291039 B6 CZ 291039B6
Authority
CZ
Czechia
Prior art keywords
sequence
amino acid
monoclonal antibody
variable region
seq
Prior art date
Application number
CZ19941910A
Other languages
Czech (cs)
English (en)
Other versions
CZ191094A3 (en
Inventor
Chuan-Chu Chou
Nicholas J. Murgolo
John S. Abrams
Chung-Her Jehn
Mary E. Petro
Jon E. Silver
Stephen Tindall
William T. Windsor
Paul J. Zavodny
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of CZ191094A3 publication Critical patent/CZ191094A3/cs
Publication of CZ291039B6 publication Critical patent/CZ291039B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CZ19941910A 1992-02-06 1993-02-04 Monoklonální protilátka, hybridom, polypeptid a způsob jeho přípravy, izolovaná DNA, rekombinantní vektor, hostitelská buňka, humanizovaná protilátka a farmaceutický prostředek CZ291039B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83284292A 1992-02-06 1992-02-06

Publications (2)

Publication Number Publication Date
CZ191094A3 CZ191094A3 (en) 1994-12-15
CZ291039B6 true CZ291039B6 (cs) 2002-12-11

Family

ID=25262763

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ19941910A CZ291039B6 (cs) 1992-02-06 1993-02-04 Monoklonální protilátka, hybridom, polypeptid a způsob jeho přípravy, izolovaná DNA, rekombinantní vektor, hostitelská buňka, humanizovaná protilátka a farmaceutický prostředek

Country Status (21)

Country Link
US (1) US6451982B1 (OSRAM)
EP (1) EP0625201A1 (OSRAM)
JP (2) JPH07505767A (OSRAM)
KR (2) KR0150060B1 (OSRAM)
CN (1) CN1077991A (OSRAM)
AR (1) AR248044A1 (OSRAM)
AU (1) AU683836B2 (OSRAM)
CA (1) CA2129445A1 (OSRAM)
CZ (1) CZ291039B6 (OSRAM)
FI (1) FI943635L (OSRAM)
HU (1) HUT67943A (OSRAM)
IL (1) IL104620A (OSRAM)
NO (1) NO942912L (OSRAM)
NZ (1) NZ249633A (OSRAM)
PL (1) PL176393B1 (OSRAM)
RU (1) RU94045919A (OSRAM)
SG (1) SG49597A1 (OSRAM)
SK (1) SK280610B6 (OSRAM)
TN (1) TNSN93012A1 (OSRAM)
WO (1) WO1993016184A1 (OSRAM)
ZA (1) ZA93779B (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU683836B2 (en) 1992-02-06 1997-11-27 Schering Corporation Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
USRE39548E1 (en) * 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US6129913A (en) * 1994-12-23 2000-10-10 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5683892A (en) 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5677280A (en) * 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) * 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5683983A (en) * 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
ATE283926T1 (de) * 1995-09-11 2004-12-15 Kyowa Hakko Kogyo Kk Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
DE60328195D1 (de) 2002-03-29 2009-08-13 Schering Corp Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
CA2501946C (en) * 2002-10-16 2014-12-23 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
JP4494977B2 (ja) 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
JP4954709B2 (ja) 2004-10-28 2012-06-20 協和発酵キリン株式会社 子宮内膜症治療剤
EP2446897A1 (en) 2005-01-06 2012-05-02 Novo Nordisk A/S Anti-KIR combination treatments and methods
EA015584B1 (ru) 2005-03-23 2011-10-31 Генмаб А/С Антитело к cd38 человека и его применение
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
PT2152290E (pt) 2007-04-30 2014-09-03 Glaxosmithkline Llc Métodos para administrar anticorpos anti-il-5
MX2010010667A (es) 2008-03-28 2010-11-09 Glaxosmithkline Llc Metodos de tratamiento.
US20110229903A1 (en) * 2008-10-23 2011-09-22 Ulrich Goepfert Determination of immunoglobulin encoding nucleic acid
AU2011349049B2 (en) 2010-12-22 2016-08-11 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
US9580501B2 (en) 2011-12-16 2017-02-28 Synthon Biopharmaceuticals B.V. Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases
US9677018B2 (en) 2013-01-09 2017-06-13 Thyssenkrupp Industrial Solutions Ag Process for the production of synthesis gas from hard coal
EP3191513B1 (en) 2014-09-08 2020-06-24 Cephalon, Inc. Use of reslizumab to treat moderate to severe eosinophilic asthma
MA42692A (fr) 2015-08-24 2018-07-04 Glaxosmithkline Ip No 2 Ltd Compositions biopharmaceutiques
CN110913887A (zh) 2017-06-06 2020-03-24 葛兰素史克有限责任公司 用于儿科患者的生物药物组合物和方法
JP2019026625A (ja) * 2017-08-03 2019-02-21 日本全薬工業株式会社 抗イヌｃｄ２０モノクローナル抗体
US11224653B2 (en) 2017-08-24 2022-01-18 Cephalon, Inc. Treatment strategy for non-responders to 100MG subcutaneous mepolizumab
BR112020005766A2 (pt) * 2017-09-29 2020-10-13 Jiangsu Hengrui Medicine Co., Ltd. anticorpo il-5, fragmento de ligação ao antígeno do mesmo, e aplicação médica do mesmo
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
ATE98872T1 (de) * 1988-11-03 1994-01-15 Schering Corp Antagonist fuer interleukin-5 zur verhuetung oder verminderung von eosinophilie.
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2041271A1 (en) * 1990-04-30 1991-10-31 Bradford A. Jameson Peptide analogs to proteins of the immunoglobin superfamily
AU683836B2 (en) 1992-02-06 1997-11-27 Schering Corporation Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5

Also Published As

Publication number Publication date
KR0150060B1 (ko) 1998-08-17
CZ191094A3 (en) 1994-12-15
NZ249633A (en) 1995-12-21
PL176393B1 (pl) 1999-05-31
WO1993016184A1 (en) 1993-08-19
KR950700413A (ko) 1995-01-16
CA2129445A1 (en) 1993-08-07
IL104620A (en) 2000-02-29
NO942912D0 (OSRAM) 1994-08-05
HU9402293D0 (en) 1994-10-28
EP0625201A1 (en) 1994-11-23
ZA93779B (en) 1993-08-05
JP2000210097A (ja) 2000-08-02
SK280610B6 (sk) 2000-05-16
SG49597A1 (en) 1998-06-15
CN1077991A (zh) 1993-11-03
US6451982B1 (en) 2002-09-17
FI943635A7 (fi) 1994-08-05
RU94045919A (ru) 1996-11-10
SK91894A3 (en) 1995-02-08
FI943635A0 (fi) 1994-08-05
AR248044A1 (es) 1995-05-31
JPH07505767A (ja) 1995-06-29
AU3656093A (en) 1993-09-03
IL104620A0 (en) 1993-06-10
FI943635L (fi) 1994-08-05
HUT67943A (en) 1995-05-29
AU683836B2 (en) 1997-11-27
NO942912L (no) 1994-10-06
TNSN93012A1 (fr) 1994-03-17

Similar Documents

Publication Publication Date Title
CZ291039B6 (cs) Monoklonální protilátka, hybridom, polypeptid a způsob jeho přípravy, izolovaná DNA, rekombinantní vektor, hostitelská buňka, humanizovaná protilátka a farmaceutický prostředek
US5863537A (en) Humanized monoclonal antibodies against human interleukin-4
JP3946256B2 (ja) ヒトインターロイキン５受容体α鎖に対する抗体
US6056957A (en) Humanized monoclonal antibodies against human interleukin-5
US8232372B2 (en) Engineered anti-TSLP antibody
CN101802015B (zh) 双特异性抗体及其制造方法
KR100697120B1 (ko) Ｉｌ-18 매개 질환의 치료에 유용한 재조합 ｉｌ-18 길항제
CN112334483B (zh) 抗IL-23p19抗体及其用途
RS55788B1 (sr) Inženjerisana anti-il-23 antitela
JP2011511638A (ja) 抗ｔｓｌｐｒ抗体の設計製作
WO1995001997A1 (en) RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
JP2002514421A (ja) Ｃｄ２３に対する抗体、それらの誘導体、及びそれらの治療的使用
JP2001509817A (ja) 抗ｖｅｇｆ抗体
SK33396A3 (en) Fusion protein with specific bond to human interleukin-4 and pharmaceutical composition containing its
EP1708961B1 (en) Anti-ip-10 antibodies
KR100509993B1 (ko) Il-5 매개된 질환의 치료에 유용한 재조합 il-5 길항제
AU2013203837A1 (en) Engineered anti-tslp antibody
HK1184172A (en) Engineered anti-tslp antibody

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 19930204